Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK's receives European Commission green light for liquid form of key vaccine
03:07am, Wednesday, 27'th Nov 2024
GSK PLC (LSE:GSK, NYSE:GSK) has received approval from the European Commission for a new, fully liquid version of its Menveo vaccine, which protects against invasive meningococcal disease (IMD) cause
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
11:25am, Tuesday, 26'th Nov 2024
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
GSK submits multiple myeloma treatment for approval to the US regulator
03:01am, Monday, 25'th Nov 2024
The US Food and Drug Administration (FDA) has accepted GSK PLC (LSE:GSK, NYSE:GSK)'s application to review the use of Blenrep (belantamab mafodotin) in treating relapsed or refractory multiple myeloma
GSK's RSV vaccine gets greenlight in Japan
04:07am, Friday, 22'nd Nov 2024
GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japan's Ministry of Health, Labour and Welfare has approved its RSV vaccine, Arexvy, for use in adults aged 50-59 at increased risk of severe RSV-related
GSK’s RSV vaccine gets greenlight in Japan
04:06am, Friday, 22'nd Nov 2024
GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japan’s Ministry of Health, Labour and Welfare has approved its RSV vaccine, Arexvy, for use in adults aged 50-59 at increased risk of severe RSV-relat
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
02:50am, Friday, 22'nd Nov 2024
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
12:00pm, Wednesday, 20'th Nov 2024
The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
GSK share price is imploding: is it safe to buy the dip?
04:05am, Tuesday, 19'th Nov 2024
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock retreated for five consecutive weeks and reached its lowest level since October las
GSK trial shows promising results for treatment of persistent itch in rare liver disease
02:54am, Tuesday, 19'th Nov 2024
GSK PLC (LSE:GSK, NYSE:GSK)has reported positive results from its phase III trial of linerixibat, a drug being tested to treat relentless itching caused by primary biliary cholangitis (PBC). PBC is a
GSK drug meets main goal in late-stage study to treat relentless itch
02:19am, Tuesday, 19'th Nov 2024
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmun
Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer
12:03pm, Monday, 18'th Nov 2024
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) Ltd has announced the appointment of Faisal Mehmud, formerly of GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer Inc (NYSE:PFE, ETR:PFE), as chief medical officer. Mehmu
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
10:03pm, Friday, 15'th Nov 2024
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De
GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
11:43am, Friday, 15'th Nov 2024
GSK plc (NYSE:GSK ) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamu
European And US Vaccine Stocks Are Under Pressure - Here's WHy
11:21am, Friday, 15'th Nov 2024
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
GSK at two-year low, drug firms hit on vaccine sceptic US health appointment
05:38am, Friday, 15'th Nov 2024
GSK PLC (LSE:GSK, NYSE:GSK) shares fell to a two-year low as AstraZeneca PLC also came under pressure on Friday after Robert F Kennedy Junior was announced as US health secretary. President-elect D
